ASX Announcement

22 March 2021

AnteoTech COVID-19 Antigen Rapid Test Clinical Study Results

Highlights

- **Verified AnteoTech COVID-19 Antigen Rapid Test[1] (ART) Sensitivity 97.3% and Specificity 99.6%**
- **Results to form the basis of CE Mark submission**
- **Technical documentation for CE Mark submitted**
- **InvestorStream Presentation "Life Science Timeline - CE Mark and Beyond"**

Brisbane based nanotechnology company AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to report the outcome of the COVID-19 ART clinical study conducted and reviewed by the Victorian Infectious Diseases Reference Laboratory (VIDRL), part of the Peter Doherty Institute for Infection and Immunity.

The study included a validation of the COVID-19 ART analytical analysis and a laboratory based clinical study to assess the accuracy and performance of the test.

All VIDRL's clinical samples used in the study were confirmed positive or negative to SARS-CoV-2 by RT-PCR and stored in Viral Transport Media (VTM), an additional and dilutive chemical element not present in the test's normal intended use.

The laboratory validation study was conducted to demonstrate that the test meets the World Health Organisation's (WHO)[2] recommended guidelines for COVID-19 antigen rapid tests with an analytical sensitivity or Limit of Detection (LoD) in the range of one million virus genome copies/mL for COVID-19 antigen rapid test.

In total, 444 deidentified nasopharyngeal samples were analysed, 184 of which were clinically diagnosed (RT-PCR confirmed) as positive for SARS-CoV-2 and 260 diagnosed as negative.

Overall COVID-19 ART sensitivity: 97.3% (179/184) and specificity 99.6% (259/260).

There was no observed cross-reactivity from common coronaviruses, MERS, Flu A, Flu B and respiratory syncytial virus or selected bacteria, meaning the analysed virus and bacteria would not produce a false positive result in this COVID-19 ART so the test is very specific.

---

1 The AnteoTech Antigen Rapid Test detects the SARS-CoV-2 active virus that causes the disease called COVID-19.

[2] WHO: Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0

The results of the study form part of the CE mark technical file submitted, by AnteoTech Ltd as the legal manufacturer of the ART.

AnteoTech CEO Derek Thomson, said: "We are delighted to have achieved this significant milestone in the development of AnteoTech's first COVID-19 ART. The study enables us to be compliant with WHO guidelines for market use of our COVID-19 antigen rapid test and provides the data required for use in our CE regulatory submission.

I'd like to thank VIDRL, for their support and guidance during the clinical study. We look forward to working with them on future test developments."

InvestorStream Presentation - Life Science Timeline - CE Mark and Beyond

CEO Derek Thomson discusses the results of the independent Analytical and Clinical Study completed by VIDRL and provides an overview of the next steps post CE Mark submission.

The interview is available at:

https://www.investorstream.com.au/anteotech-release-march

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: https://twitter.com/AnteoTech or visit www.anteotech.com